Ertapenem
- Generic Name
- Ertapenem
- Brand Names
- Invanz, Ertapenem SUN
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N3O7S
- CAS Number
- 153832-46-3
- Unique Ingredient Identifier
- G32F6EID2H
- Background
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.
- Indication
Ertapenem is indicated to treat the following moderate to severe infections caused by susceptible bacteria in adult and pediatric patients (three months of age and older):
Ertapenem is also used in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
- Associated Conditions
- Acute Gynecological Infection, Severe Community-acquired Pneumonia (sCAP), Surgical Site Infections, Acute, moderate Pelvic Infections caused by susceptible bacteria, Acute, severe susceptible bacteria Pelvic Infections, Moderate Community acquired pneumonia, Moderate Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Moderate Diabetic Foot Infection, Moderate Gynaecological infection caused by susceptible bacteria, Moderate Postpartum Endomyometritis caused by susceptible bacteria, Moderate Septic Abortion caused by susceptible bacteria, Moderate complicated Urinary Tract Infection caused by susceptible bacteria, Moderate complicated skin and skin-structure infections caused by susceptible bacteria, Severe Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Severe Diabetic Foot Infection, Severe Gynaecological infection caused by susceptible bacteria, Severe Postpartum Endomyometritis caused by susceptible bacteria, Severe Septic Abortion caused by susceptible bacteria, Severe complicated Urinary Tract Infection caused by susceptible bacteria, Severe complicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 552
- Registration Number
- NCT03236961
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 147
- Registration Number
- NCT03234296
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Khon Kaen University
- Target Recruit Count
- 30
- Registration Number
- NCT02729116
- Locations
- 🇹🇭
Khon Kaen University, Ban Khanaen, Khonkaen, Thailand
Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 96
- Registration Number
- NCT02537847
- Locations
- 🇹🇭
Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
Pharmacokinetics of Ertapenem in Patients Aged Over 75
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 27
- Registration Number
- NCT02505386
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 7
- Registration Number
- NCT02159859
- Locations
- 🇺🇸
Oakwood Hospital - Dearborn, Dearborn, Michigan, United States
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT02041767
- Locations
- 🇫🇷
HEGP Hospital, Paris, France
A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT01937832
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, Jilin, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 189
- Registration Number
- NCT01886053
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.